As the costs of drug development escalate, pharmaceutical companies are demanding high quality early stage data to increase confidence in the efficacy and safety of compounds before they enter expensive and lengthy animal and clinical trials.  To meet this demand, high throughput screening (HTS) is relied upon to improve productivity and selection of the best lead compounds earlier in the drug discovery process.  While HTS continues to advance, it presents challenges in terms of the expenditure of time to develop assays, and the costs of reagents to execute them.  Hence there is heightened demand for assays that are quicker to establish and less expensive to run than current assay platforms, yet are robust and high throughput. 

Join Frost & Sullivan and Caldera as we highlight a new assay platform based on label-free molecular X-ray fluorescence.  This new application of a well known semiconductor technology has unique advantages for HTS in significantly shortening assay development time and drastically reducing reagent costs.

Learn how molecular X-ray fluorescence addresses bottlenecks in enzymatic assay development and high-throughput functional screening. Click here to register and join us as we answer many of your challenging questions and join us for a Q&A session with the presenters.